Guardian Capital (Canada)’s Novo Nordisk NVO Stock Holding History

Guardian Capital (Canada)’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-18,200	Closed	-$1.84M	–	148
2024 Q3	$1.84M	Buy	+18,200	New	+$2.43M	0.07%	108
2024 Q1	–	Sell	-35,200	Closed	-$1.74M	–	156
2023 Q4	$1.74M	Buy	+35,200	New	+$3.48M	0.06%	106
2023 Q2	–	Sell	-59,800	Closed	-$762K	–	159
2023 Q1	$762K	Buy	+59,800	New	+$4.24M	0.02%	132
2022 Q4	–	Sell	-77,400	Closed	-$2.02M	–	177
2022 Q3	$2.02M	Buy	77,400 +2,400	+3%	+$129K	0.07%	93
2022 Q2	$1.2M	Buy	75,000 +4,400	+6%	+$244K	0.04%	122
2022 Q1	$1.18M	Buy	70,600 +4,400	+7%	+$226K	0.02%	129
2021 Q4	$627K	Buy	66,200 +7,800	+13%	+$423K	0.01%	154
2021 Q3	$1.07M	Sell	58,400 -2,400	-4%	-$116K	0.02%	134
2021 Q2	$189K	Buy	+60,800	New	+$2.36M	﹤0.01%	162

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Guardian Capital (Canada)'s NVO Position: Q4 2025 in Review

Guardian Capital (Canada) sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 19,213 shares — an estimated $1.07M sold.

Guardian Capital (Canada) first reported a position in NVO in Q2 2013 and held it in 40 quarters. The position peaked at $30M in Q2 2024. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

Guardian Capital (Canada) reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
Guardian Capital (Canada) sold 19,213 Novo Nordisk shares in Q4 2025, an estimated $1.07M.
Guardian Capital (Canada) first reported a position in Novo Nordisk in Q2 2013 and held it in 40 quarters.
Guardian Capital (Canada)'s Novo Nordisk position peaked at $30M in Q2 2024.
1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Guardian Capital (Canada)'s 13F filing for Q4 2025, filed 18 Feb 2026.